Supplements

VEGF Inhibitors and Ophthalmic Diseases

This supplement is provided by Regeneron Pharmaceuticals, Inc.

 

Vascular endothelial growth factor (VEGF) has demonstrated to be central to the pathology of several ophthalmic diseases.1 Anti-VEGF therapy has dramatically improved the prognosis of many of these common vision-threatening retinal diseases. Click here to review current treatments of these diseases, with an emphasis on anti-VEGF therapy. 

 

Click here to read the supplement.

Author

Mitchell J. Goff, MD
Retina Specialist
Rocky Mountain Retinal Consultants
Salt Lake City, UT

 

1. Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248-1264.

 

 

EYL.20.06.0028 07/2020

Recommended Reading

Germline testing in advanced cancer can lead to targeted treatment
Federal Practitioner
Acute lymphoblastic leukemia can be successfully treated in the frail elderly
Federal Practitioner
Atopic dermatitis in adults, children linked to neuropsychiatric disorders
Federal Practitioner
Is cannabis gaining acceptance as a treatment for neuropathic pain?
Federal Practitioner
Americans avoided emergency departments early in the pandemic
Federal Practitioner
Sex-based disparities in liver allocation driven by organ size mismatch, MELD score
Federal Practitioner
‘Promising’ durvalumab results spark phase 3 trial in mesothelioma
Federal Practitioner
Most rheumatology drugs don’t increase COVID-19 hospitalization risk
Federal Practitioner
Should healthcare workers wear masks at home?
Federal Practitioner
Lancet, NEJM retract studies on hydroxychloroquine for COVID-19
Federal Practitioner